Blood safety--a focus on plasma derivatives in Mainland China.
Plasma derivative production in Mainland China can be encapsulated by two figures: 50 years of history and 5000 tons of annually processed source plasma. Demands for albumin, immunoglobulinin and main clotting factors can barely be met, despite a relatively low average usage among China's population of 1.3 billion. The tragedy of contamination among plasma donors in Henan province in the early 1990's has left shadows on the safety of the plasma derivative industry. However, during the last ten years the Chinese government has made great strides forward. The regulation of the entire operation has been strengthened, from law and standard setting and upholding to stricter licensing regulations for plasma centers and fractionators. Public concerns in blood safety are gradually being relieved, and confidence is returning. Nevertheless, the plasma donors and hemophilia patients infected a decade ago by infected blood or plasma products represent a set of severe social and medical problems that the government and society must still deal with.
Zhu
Y M
YM
Shanghai Blood Center, Shanghai, China. ymzhu@sbc.org.cn
D001688:Biological Products; D001803:Blood Transfusion / Q000331:legislation & jurisprudence / Q000592:standards*; D002681:China; D033161:Government Regulation; D006801:Humans; D010949:Plasma / Q000737:chemistry*; D011785:Quality Assurance, Health Care
D001688:Biological Products